Protein‑Protein Interaction (PPI) Inhibitory Peptide Testing

Protein‑Protein Interaction (PPI) Inhibitory Peptide Testing – Affinity, Potency, Specificity, and Cellular Validation

If you are searching for PPI inhibitory peptide testing, you likely need to determine whether a candidate peptide can effectively disrupt a specific protein‑protein interaction, and to what extent. This is essential for drug discovery (targeting disease‑relevant interfaces), tool compound validation, mechanistic studies, or peptide drug optimization. Unlike conventional enzyme inhibition assays, PPI inhibition requires measuring direct binding, competition, and disruption of complex formation. Our laboratory provides comprehensive inhibitory peptide characterization – from binding affinity and IC₅₀ determination to functional cellular assays, selectivity profiling, and structural mapping – using orthogonal biophysical and cell‑based platforms.

What We Analyze – Complete Inhibitory Peptide Profiling

We do not simply report “inhibition observed”. Our platform includes Surface Plasmon Resonance (SPR) (Biacore 8K+, S200) to measure binding affinity (K_D) of the peptide to its target protein as well as competition with the natural binding partner. For direct inhibition potency, we perform AlphaScreen/AlphaLISA, TR‑FRET, or homogeneous time‑resolved fluorescence (HTRF) assays to measure IC₅₀ (half‑maximal inhibitory concentration) in a dose‑dependent manner. We also use MicroScale Thermophoresis (MST) and Isothermal Titration Calorimetry (ITC) to determine binding stoichiometry and thermodynamics (ΔH, ΔS) in solution, without immobilization artifacts. For selectivity profiling, we test the peptide against a panel of related protein‑protein interactions (e.g., same domain family, off‑target interfaces) using competitive SPR or ELISA. Cellular activity is evaluated using NanoBRET, protein fragment complementation assays (PCA), co‑immunoprecipitation (co‑IP) from cell lysates, or proximity ligation assays (PLA) to confirm inhibition in live cells. We also assess peptide stability in serum, cell lysate, or simulated physiological buffers by HPLC‑MS, and cell permeability (if not using delivery vectors) by quantitative mass spectrometry or fluorescence imaging. To map the binding interface, we offer alanine scanning (single‑residue substitution peptides) and HDX‑MS (hydrogen‑deuterium exchange mass spectrometry) on the target protein in the presence vs. absence of the inhibitory peptide.

Key parameters we routinely deliver:
- Binding affinity (K_D) of peptide to target protein – from pM to µM range, by SPR, MST, or ITC.
- Inhibitory potency (IC₅₀, EC₅₀) – in biochemical or cell‑based assays, with Hill coefficient.
- Competition mode (competitive, non‑competitive, allosteric) – determined by SPR binding in presence of competitor.
- Selectivity ratio (IC₅₀(off‑target)/IC₅₀(target)) – using orthogonal PPI assay panels.
- Cellular target engagement (NanoBRET or PLA) – quantitative measure of PPI disruption in live cells.
- Metabolic stability (t_1/2 in mouse/human serum, plasma, or liver microsomes) – LC‑MS quantification.
- Peptide‑induced conformational changes on target protein – by HDX‑MS or CD spectroscopy.
- Binding interface residues (alanine scan or cross‑linking MS) – mapping critical peptide residues and contact sites on the protein.
- Effective concentration in cell culture (EC₅₀ for downstream functional readout, e.g., gene expression, proliferation, or signaling) – optional.
- Reversibility (by dissociation rate measurements or washout experiments) – via SPR or cell‑based washout.

How Deep We Go – Sub‑nanomolar Sensitivity, Complex Interface Mapping, and In Vivo Mimetic Profiling

Most routine PPI peptide testing labs only measure IC₅₀ in a single biochemical assay, often missing off‑target effects or cellular activity. We provide orthogonal validation using at least two independent biophysical methods (e.g., SPR + MST) to confirm K_D and IC₅₀. For low‑affinity or transient interactions, we use KinExA (kinetic exclusion assay) to measure K_D down to 10 pM and extremely slow off‑rates. For membrane protein complexes (e.g., GPCR heterodimers), we use nanodisc‑reconstituted target proteins in SPR or MST, preserving native lipid environment. To determine the minimal inhibitory motif, we synthesize and test truncated, stapled, and D‑amino acid substituted variants in parallel.

For cellular potency, we go beyond simple reporter assays: we measure endogenous protein‑protein interaction disruption by proximity ligation assay (PLA) with quantitative image analysis, and functional consequences such as inhibition of downstream signaling (phosphoprotein flow cytometry or Western blot) with a full dose‑response. Our proteome‑wide selectivity screening uses mass spectrometry‑based thermal stability profiling (CETSA‑MS) or affinity pull‑down with whole cell lysates followed by LC‑MS/MS to identify off‑target binding proteins. This level of selectivity information is rarely available from commercial providers.

We also perform in vitro ADME (absorption, distribution, metabolism, excretion) assays tailored to peptides: plasma protein binding, Caco‑2 permeability (or PAMPA with peptide modifications), and metabolic stability in liver S9 fractions. For lead optimization, we provide structure‑activity relationship (SAR) tables for >50 peptide variants, including correlation of sequence modifications with affinity, stability, and cellular activity.

Advanced capabilities include:
- Single‑cell interaction mapping (for rare cell populations or primary cells) – using microfluidic‑based protein interaction assays.
- Real‑time PPI disruption kinetics in living cells by BRET – with millisecond temporal resolution.
- X‑ray crystallography or cryo‑EM for peptide‑target complex structure – when full 3D structural validation is required (we partner with structural biology core).
- Peptide cyclization (disulfide, hydrocarbon stapling) and testing – to improve stability and helicity.
- In vivo proof‑of‑concept study (optional) – including peptide administration (IP, IV) and target engagement measurement in animal tissues.
- Quantitative analysis of peptide‑induced protein degradation (PROTAC‑like) – if the peptide recruits an E3 ligase.

We routinely achieve measurement uncertainties: K_D ±10‑15% (SPR), IC₅₀ ±0.2 log units; selectivity >50‑fold considered specific; cellular activity correlation with biochemical potency (R² >0.8 for direct competitors). All methods follow FDA guidance for biochemical and cell‑based potency assays (ICH Q2, Q14) and best practices for PPI inhibitors (Druggability Guidelines).

Why Choose Our PPI Inhibitory Peptide Testing – Key Advantages

1. ISO/IEC 17025:2017 accredited and GLP‑compliant workflows – suitable for lead optimization, pre‑clinical candidate selection, and regulatory filing.
2. Orthogonal validation (biochemical, biophysical, cell‑based, and selectivity panels) – we never rely on a single assay, reducing false leads.
3. Ultra‑high sensitivity for weak or transient PPI inhibitors (pM to µM range) – using KinExA and nano‑ITC for challenging targets.
4. Comprehensive selectivity profiling (proteome‑wide MS or 50+ off‑target PPI panels) – we identify potential toxicity liabilities early.
5. Cellular activity in disease‑relevant models (primary cells, organoids, or 3D cultures) – we can perform functional end‑point assays specific to your pathway.
6. Structural mapping (alanine scan, HDX‑MS, and optional crystallography) – enabling rational peptide optimization.
7. Fast turnaround with full data transparency – binding affinity + IC₅₀ in biochemical assay for 1 peptide in 3‑5 business days; full panel (affinity, potency, selectivity, cellular, stability) in 10‑12 business days. You receive raw sensorgrams, MST curves, dose‑response plots, PLA images, and a complete report.
8. Custom development for novel or proprietary protein targets (no commercial kits) – we develop all reagents (protein expression, labeling, cell lines) within 4‑6 weeks.
9. Competitive pricing for complete inhibitory peptide characterization packages – bundling K_D, IC₅₀ (biochemical & cellular), selectivity (8 off‑targets), and serum stability costs 35% less than separate orders.

We have successfully completed over 300 PPI inhibitory peptide projects for pharmaceutical companies, biotech startups, and academic drug discovery groups. Our team includes PhD biochemists, cell biologists, and mass spectrometrists specialized in protein‑protein interaction modulation.

Ready to Test Your PPI Inhibitory Peptide?

Provide your target protein pair (e.g., “p53‑HDM2”, “PD‑1/PD‑L1”, “RAS‑RAF”), the peptide sequence or source, and the desired application (e.g., “tool inhibitor”, “lead optimization”, “cellular validation”). We will provide a free technical consultation, a recommended testing cascade, and a fixed‑price quote. Whether you need a rapid confirmation of inhibition or a full pre‑clinical characterization package, we deliver deep, accurate, and biologically relevant PPI inhibitory peptide testing tailored to your drug discovery program.